SCOPUS 정보 검색 플랫폼

Volumn 77, Issue 1, 2011, Pages 254-255

Re: Tollefson et al.: Surgical treatment of renal cell carcinoma in the immunocompromised transplant patient (Urology 2010;75:1373-1377)

(5) Chueh, Shih Chieh Jeff a Flechner, Stuart a Goldfarb, David a Sankari, Bashir R a Campbell, Steven a

a LERNER RESEARCH INSTITUTE (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCINEURIN INHIBITOR; CYCLOSPORIN; INTERFERON; INTERLEUKIN 2; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR;

CANCER IMMUNOTHERAPY; CANCER SURGERY; DENDRITIC CELL; FOLLOW UP; FOOD AND DRUG ADMINISTRATION; GRAFT RECIPIENT; HUMAN; IMMUNOCOMPROMISED PATIENT; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY CANCER; KIDNEY CARCINOMA; LETTER; METASTASIS; MORTALITY; PRIORITY JOURNAL; SURGICAL TECHNIQUE; TREATMENT OUTCOME; TUMOR IMMUNITY;

CARCINOMA, RENAL CELL; HUMANS; IMMUNOCOMPROMISED HOST; IMMUNOSUPPRESSION; KIDNEY NEOPLASMS; ORGAN TRANSPLANTATION;

EID: 78650869231 PISSN: 00904295 EISSN: 15279995 Source Type: Journal
DOI: 10.1016/j.urology.2010.09.058 Document Type: Letter

Times cited : (2)

References (5)

1
- 77952742173
- Surgical treatment of renal cell carcinoma in the immunocompromised transplant patient
- M.K. Tollefson, A.E. Krambeck, and B.C. Leibovich Surgical treatment of renal cell carcinoma in the immunocompromised transplant patient Urology 75 2010 1373 1377
- (2010) Urology , vol.75 , pp. 1373-1377
- Tollefson, M.K.¹ Krambeck, A.E.² Leibovich, B.C.³

2
- 68049140780
- Clinical and immunologic effects of intranodal autologous tumor lysate-dendritic cell vaccine with aldesleukin (interleukin 2) and IFN-{alpha}2a therapy in metastatic renal cell carcinoma patients
- T. Schwaab, A. Schwarzer, and B. Wolf Clinical and immunologic effects of intranodal autologous tumor lysate-dendritic cell vaccine with aldesleukin (interleukin 2) and IFN-{alpha}2a therapy in metastatic renal cell carcinoma patients Clin Cancer Res 15 2009 4986 4992
- (2009) Clin Cancer Res , vol.15 , pp. 4986-4992
- Schwaab, T.¹ Schwarzer, A.² Wolf, B.³

3
- 61349116156
- EORTC-GU group expert opinion on metastatic renal cell cancer
- T.M. de Reijke, J. Bellmunt, H. van Poppel, S. Marreaud, and M. Aapro EORTC-GU group expert opinion on metastatic renal cell cancer Eur J Cancer 45 2009 765 773
- (2009) Eur J Cancer , vol.45 , pp. 765-773
- De Reijke, T.M.¹ Bellmunt, J.² Van Poppel, H.³ Marreaud, S.⁴ Aapro, M.⁵

4
- 77956227464
- Phase 3 trial of everolimus for metastatic renal cell carcinoma: Final results and analysis of prognostic factors
- RECORD-1 Study Group S.
- R.J. Motzer, B. Escudier, S. Oudard RECORD-1 Study Group Phase 3 trial of everolimus for metastatic renal cell carcinoma : final results and analysis of prognostic factors Cancer 116 2010 4256 4265
- (2010) Cancer , vol.116 , pp. 4256-4265
- Motzer, R.J.¹ Escudier, B.² Oudard, S.³

5
- 77951729433
- FDA approval summary: Temsirolimus as treatment for advanced renal cell carcinoma
- V.E. Kwitkowski, T.M. Prowell, and A. Ibrahim FDA approval summary: temsirolimus as treatment for advanced renal cell carcinoma Oncologist 15 2010 428 435
- (2010) Oncologist , vol.15 , pp. 428-435
- Kwitkowski, V.E.¹ Prowell, T.M.² Ibrahim, A.³

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.